1
|
salah E, El esh H, Abdel-Reheim ES, Abdul-Hamid M. Ameliorative effects of Artemisia and Echinacea extracts against hepato and cardiotoxicity induced by DMBA on albino rats: experimental and molecular docking analyses. BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES 2022. [DOI: 10.1186/s43088-022-00286-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Herbal therapy for healing disease has many advantages than drugs. This study investigates the protective efficacy of Artemisia annua (Art) and Echinacea pupurea (Ech) extracts against 7, 12-dimethylbenz (α) anthracene (DMBA) toxicity.
Results
DMBA-treated rats showed a significant increase in the level of serum ALT, AST, LDH and CKMB, also reduction in body weight gain (BWG) ℅, HB, WBCs, RBCs and platelet counts, in addition to histopathological and ultrastructural alterations. Rats treated with Art or Ech after DMBA showed little improvements in the biochemical, hematological, histopathological, ultrastructural and molecular docking results than before DMBA.
Conclusions
This study suggested the ameliorative effect of Ech and Art due to their antioxidant properties, but Ech and Art were more effective if they are given before than after DMBA administration and the marked effect against DMBA toxicity with Ech before DMBA exposure. Also, the molecular docking, molecular properties descriptors, and pharmacoinformatic studies of constituents of extract from Artemisia annua L. and Echinacea purpurea L. exhibited that all studied compounds have better ADMET and physicochemical properties, especially compounds extract from Echinacea purpurea L.
Graphical Abstract
Collapse
|
2
|
Aucoin M, Cardozo V, McLaren MD, Garber A, Remy D, Baker J, Gratton A, Kala MA, Monteiro S, Warder C, Perciballi A, Cooley K. A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19? Metabol Open 2021; 11:100115. [PMID: 34341776 PMCID: PMC8320399 DOI: 10.1016/j.metop.2021.100115] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 07/26/2021] [Accepted: 07/26/2021] [Indexed: 12/15/2022] Open
Abstract
COVID-19 is the respiratory illness caused by the novel coronavirus, SARS-CoV-2. Cytokine storm appears to be a factor in COVID-19 mortality. Echinacea species have been used historically for immune modulation. A previous rapid review suggested that Echinacea supplementation may decrease the levels of pro-inflammatory cytokines involved in cytokine storm. The objective of the present systematic review was to identify all research that has assessed changes in levels of cytokines relevant to cytokine storm in response to administration of Echinacea supplementation. The following databases were searched: Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid). Title and abstract screening, full text screening, and data extraction were completed in duplicate using a piloted extraction template. Risk of bias assessment was completed. Qualitative analysis was used to assess for trends in cytokine level changes. The search identified 279 unique publications. After full text screening, 105 studies met criteria for inclusion including 13 human studies, 24 animal studies, and 71 in vitro or ex vivo studies. The data suggest that Echinacea supplementation may be associated with a decrease in the pro-inflammatory cytokines IL-6, IL-8, and TNF, as well as an increase in the anti-inflammatory cytokine IL-10. The risk of bias in the included studies was generally high. While there is currently no substantive research on the therapeutic effects of Echinacea in the management of either cytokine storm or COVID-19, the present evidence related to the herb's impact on cytokine levels suggests that further research may be warranted in the form of a clinical trial involving patients with COVID-19.
Collapse
Key Words
- ARDS, acute respiratory distress syndrome
- CCL, C–C motif ligand chemokine
- COVID-19
- COVID-19, coronavirus disease 2019
- CSF, Colony-stimulating factor
- Cytokine
- Cytokine release syndrome
- Cytokine storm
- Echinacea
- GM-CSF, granulocyte-macrophage colony-stimulating factor
- Herbal medicine
- IFN, interferon
- IL, interleukin
- MCP, monocyte chemoattractant protein
- MIP, macrophage inflammatory protein
- SARS, Severe acute respiratory syndrome
- SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- TFN, tumor necrosis factor
Collapse
Affiliation(s)
| | | | | | - Anna Garber
- Canadian College of Naturopathic Medicine, Canada
| | - Daniella Remy
- Canadian College of Naturopathic Medicine, Canada
- ph360.me/Shae, Australia
| | - Joy Baker
- Canadian College of Naturopathic Medicine, Canada
| | - Adam Gratton
- Canadian College of Naturopathic Medicine, Canada
| | | | | | - Cara Warder
- Canadian College of Naturopathic Medicine, Canada
| | | | - Kieran Cooley
- Canadian College of Naturopathic Medicine, Canada
- University Technology, Sydney, Australia
- National Centre for Naturopathic Medicine at Southern Cross University, Australia
- Pacific College of Health and Science, United States
| |
Collapse
|
3
|
Nagoor Meeran M, Javed H, Sharma C, Goyal SN, Kumar S, Jha NK, Ojha S. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon 2021; 7:e05990. [PMID: 33585706 PMCID: PMC7870107 DOI: 10.1016/j.heliyon.2021.e05990] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 12/18/2020] [Accepted: 01/11/2021] [Indexed: 02/06/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an ongoing public health emergency. The pathogenesis and complications advanced with infection mainly involve immune-inflammatory cascade. Therefore, the therapeutic strategy relies on immune modulation, reducing infectivity and inflammation. Given the interplay of infection and immune-inflammatory axis, the natural products received attention for preventive and therapeutic usage in COVID-19 due to their potent antiviral and anti-immunomodulatory activities. Recently, Echinacea preparations, particularly E. purpurea, have been suggested to be an important antiviral agent to be useful in COVID-19 by modulating virus entry, internalization and replication. In principle, the immune response and the resultant inflammatory process are important for the elimination of the infection, but may have a significant impact on SARS-CoV-2 pathogenesis and may play a role in the clinical spectrum of COVID-19. Considering the pharmacological effects, therapeutic potential, and molecular mechanisms of Echinacea, we hypothesize that it could be a reasonably possible candidate for targeting infection, immunity, and inflammation in COVID-19 with recent recognition of cannabinoid-2 (CB2) receptors and peroxisome proliferator-activated receptor gamma (PPARγ) mediated mechanisms of bioactive components that make them notable immunomodulatory, anti-inflammatory and antiviral agent. The plausible reason for our hypothesis is that the presence of numerous bioactive agents in different parts of plants that may synergistically exert polypharmacological actions in regulating immune-inflammatory axis in COVID-19. Our proposition is to scientifically contemplate the therapeutic perspective and prospect of Echinacea on infection, immunity, and inflammation with a potential in COVID-19 to limit the severity and progression of the disease. Based on the clinical usage for respiratory infections, and relative safety in humans, further studies for the evidence-based approach to COVID-19 are needed. We do hope that Echinacea could be a candidate agent for immunomodulation in the prevention and treatment of COVID-19.
Collapse
Affiliation(s)
- M.F. Nagoor Meeran
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Hayate Javed
- Department of Anatomy, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Charu Sharma
- Department of Internal Medicine, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Sameer N. Goyal
- Shri Vile Parle Kelvani Mandal's Institute of Pharmacy, Dhule 424001, Maharashtra, India
| | - Sanjay Kumar
- Division of Hematology/Nephrology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
- Department of Life Sciences, School of Basic Science and Research, Sharda University, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India
| | - Niraj Kumar Jha
- Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India
| | - Shreesh Ojha
- Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, PO Box - 17666, United Arab Emirates University, Al Ain, United Arab Emirates
| |
Collapse
|
4
|
Salvadori L, Mandrone M, Manenti T, Ercolani C, Cornioli L, Lianza M, Tomasi P, Chiappalupi S, Di Filippo ES, Fulle S, Poli F, Sorci G, Riuzzi F. Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia. Nutrients 2020; 13:E49. [PMID: 33375229 PMCID: PMC7824275 DOI: 10.3390/nu13010049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 12/18/2020] [Accepted: 12/21/2020] [Indexed: 12/11/2022] Open
Abstract
Background: Muscle atrophy, i.e., the loss of skeletal muscle mass and function, is an unresolved problem associated with aging (sarcopenia) and several pathological conditions. The imbalance between myofibrillary protein breakdown (especially the adult isoforms of myosin heavy chain, MyHC) and synthesis, and the reduction of muscle regenerative potential are main causes of muscle atrophy. Methods: Starting from one-hundred dried hydroalcoholic extracts of medical plants, we identified those able to contrast the reduction of C2C12 myotube diameter in well-characterized in vitro models mimicking muscle atrophy associated to inflammatory states, glucocorticoid treatment or nutrient deprivation. Based on their ability to rescue type II MyHC (MyHC-II) expression in atrophying conditions, six extracts with different phytochemical profiles were selected, mixed in groups of three, and tested on atrophic myotubes. The molecular mechanism underpinning the effects of the most efficacious formulation, and its efficacy on myotubes obtained from muscle biopsies of young and sarcopenic subjects were also investigated. Results: We identified WST (Withania somnifera, Silybum marianum, Trigonella foenum-graecum) formulation as extremely efficacious in protecting C2C12 myotubes against MyHC-II degradation by stimulating Akt (protein kinase B)-dependent protein synthesis and p38 MAPK (p38 mitogen-activated protein kinase)/myogenin-dependent myoblast differentiation. WST sustains trophism in C2C12 and young myotubes, and rescues the size, developmental MyHC expression and myoblast fusion in sarcopenic myotubes. Conclusion: WST strongly counteracts muscle atrophy associated to different conditions in vitro. The future validation in vivo of our results might lead to the use of WST as a food supplement to sustain muscle mass in diffuse atrophying conditions, and to reverse the age-related functional decline of human muscles, thus improving people quality of life and reducing social and health-care costs.
Collapse
Affiliation(s)
- Laura Salvadori
- Department Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy;
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
| | - Manuela Mandrone
- Department Pharmacy and Biotechnology (FaBiT), University of Bologna, 40126 Bologna, Italy; (M.M.); (M.L.); (P.T.); (F.P.)
| | - Tommaso Manenti
- Biokyma srl Laboratories, 52031 Anghiari, Italy; (T.M.); (C.E.); (L.C.)
| | - Catia Ercolani
- Biokyma srl Laboratories, 52031 Anghiari, Italy; (T.M.); (C.E.); (L.C.)
| | - Luca Cornioli
- Biokyma srl Laboratories, 52031 Anghiari, Italy; (T.M.); (C.E.); (L.C.)
| | - Mariacaterina Lianza
- Department Pharmacy and Biotechnology (FaBiT), University of Bologna, 40126 Bologna, Italy; (M.M.); (M.L.); (P.T.); (F.P.)
| | - Paola Tomasi
- Department Pharmacy and Biotechnology (FaBiT), University of Bologna, 40126 Bologna, Italy; (M.M.); (M.L.); (P.T.); (F.P.)
| | - Sara Chiappalupi
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
- Department Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
| | - Ester Sara Di Filippo
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
- Department Neuroscience, Imaging and Clinical Sciences, University G. D’Annunzio Chieti e Pescara, 66100 Chieti, Italy
| | - Stefania Fulle
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
- Department Neuroscience, Imaging and Clinical Sciences, University G. D’Annunzio Chieti e Pescara, 66100 Chieti, Italy
| | - Ferruccio Poli
- Department Pharmacy and Biotechnology (FaBiT), University of Bologna, 40126 Bologna, Italy; (M.M.); (M.L.); (P.T.); (F.P.)
| | - Guglielmo Sorci
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
- Department Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
| | - Francesca Riuzzi
- Interuniversity Institute of Myology (IIM), 06132 Perugia, Italy; (S.C.); (E.S.D.F.); (S.F.); (G.S.)
- Department Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
| |
Collapse
|
5
|
Salybekov AA, Salybekova AK, Pola R, Asahara T. Sonic Hedgehog Signaling Pathway in Endothelial Progenitor Cell Biology for Vascular Medicine. Int J Mol Sci 2018; 19:E3040. [PMID: 30301174 PMCID: PMC6213474 DOI: 10.3390/ijms19103040] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2018] [Revised: 09/28/2018] [Accepted: 10/01/2018] [Indexed: 01/08/2023] Open
Abstract
The Hedgehog (HH) signaling pathway plays an important role in embryonic and postnatal vascular development and in maintaining the homeostasis of organs. Under physiological conditions, Sonic Hedgehog (SHH), a secreted protein belonging to the HH family, regulates endothelial cell growth, promotes cell migration and stimulates the formation of new blood vessels. The present review highlights recent advances made in the field of SHH signaling in endothelial progenitor cells (EPCs). The canonical and non-canonical SHH signaling pathways in EPCs and endothelial cells (ECs) related to homeostasis, SHH signal transmission by extracellular vesicles (EVs) or exosomes containing single-strand non-coding miRNAs and impaired SHH signaling in cardiovascular diseases are discussed. As a promising therapeutic tool, the possibility of using the SHH signaling pathway for the activation of EPCs in patients suffering from cardiovascular diseases is further explored.
Collapse
Affiliation(s)
- Amankeldi A Salybekov
- Department of Regenerative Medicine Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
| | - Ainur K Salybekova
- Department of Regenerative Medicine Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
| | - Roberto Pola
- Department of Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.
| | - Takayuki Asahara
- Department of Regenerative Medicine Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.
| |
Collapse
|
6
|
Kröpfl JM, Spengler CM, Frobert A, Ajalbert G, Giraud MN. Myocardial infarction does not affect circulating haematopoietic stem and progenitor cell self-renewal ability in a rat model. Exp Physiol 2017; 103:1-8. [PMID: 29094480 DOI: 10.1113/ep086643] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 10/31/2017] [Indexed: 12/16/2022]
Abstract
NEW FINDINGS What is the central question of this study? Although peripheral blood haematopoietic stem and progenitor cells are potentially important in regeneration after acute myocardial infarction, their self-renewal ability in the post-acute phase has not yet been addressed. What is the main finding and its importance? In rat peripheral blood, we show that myocardial infarction does not negatively affect circulating haematopoietic stem and progenitor cell self-renewal ability 2 weeks after acute infarction, which suggests a constant regenerative potential in the myocardial infarction post-acute phase. Given the importance of peripheral blood haematopoietic stem and progenitor cells (HPCs) in post-acute regeneration after acute myocardial infarction (MI), the aim of the present study was to investigate the number and secondary replating capacity/self-renewal ability of HPCs in peripheral blood before and 2 weeks after MI. In female Lewis inbred rats (n = 9), MI was induced by ligation of the left coronary artery, and another nine underwent sham surgery, without ligation, for control purposes. Myocardial infarction was confirmed by troponin I concentrations 24 h after surgery. Peripheral blood was withdrawn and fractional shortening and ejection fraction of the left ventricle were assessed before (day 0) and 14 days after MI or sham surgery (day 14). After mononuclear cell isolation, primary and secondary functional colony-forming unit granulocyte-macrophage (CFU-GM) assays were performed in order to detect the kinetics of functional HPC colony counts and cell self-renewal ability in vitro. The CFU-GM counts and cell self-renewal ability remained unchanged (P > 0.05) in both groups at day 14, without interaction between groups. In the intervention group, higher day 0 CFU-GM counts showed a relationship to lower fractional shortening on day 14 (ρ = -0.82; P < 0.01). Myocardial infarction did not negatively affect circulating HPC self-renewal ability, which suggests a constant regenerative potential in the post-acute phase. A relationship of cardiac contractile function 14 days after MI with circulating CFU-GM counts on day 0 might imply functional colony count as a predictive factor for outcome after infarction.
Collapse
Affiliation(s)
- J M Kröpfl
- Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland
| | - C M Spengler
- Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland
| | - A Frobert
- Cardiology, University of Fribourg, Fribourg, Switzerland
| | - G Ajalbert
- Cardiology, University of Fribourg, Fribourg, Switzerland
| | - M N Giraud
- Cardiology, University of Fribourg, Fribourg, Switzerland
| |
Collapse
|
7
|
Simultaneous Determination of Seven Phenolic Acids in Rat Plasma Using UHPLC-ESI-MS/MS after Oral Administration of Echinacea purpurea Extract. Molecules 2017; 22:molecules22091494. [PMID: 28880243 PMCID: PMC6151385 DOI: 10.3390/molecules22091494] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Accepted: 09/04/2017] [Indexed: 12/31/2022] Open
Abstract
A rapid and sensitive Ultra High Performance Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (UHPLC-ESI-MS/MS) method was developed and validated to simultaneously determine the concentration of seven phenolic acids (syringic acid, ferulic acid, caffeic acid, vanillic acid, p-coumaric acid, 3,4-dihydroxybenzoic acid and 4-hydroxybenzoic acid) in rat plasma after oral administration of Echinacea purpurea extract. After mixing with the internal standard (IS), butylparaben, plasma samples were prepared by liquid–liquid extraction with ethyl acetate. The separation was performed using the Agilent Eclipse Plus C18 column (1.8 μm, 2.1 mm × 50 mm) with a gradient system consisting of solution A (0.1% acetic acid in water) and solution B (methanol) at a flow rate of 0.3 mL/min. The detection was accomplished by a multiple reaction monitoring (MRM) mode with electrospray ionization (ESI). The method was validated in terms of linearity, precision, accuracy, extraction recovery, matrix effect and stability. This method was successfully applied to study the pharmacokinetic properties of the seven compounds after oral administration of Echinacea purpurea extract in rats.
Collapse
|
8
|
Gan C, Liu L, Du Y, Wang L, Gao M, Wu L, Yang C. Simultaneous determination and pharmacokinetic study of four phenol compounds in rat plasma by ultra-high performance liquid chromatography with tandem mass spectrometry after oral administration of Echinacea purpurea
extract. J Sep Sci 2016; 39:1628-37. [DOI: 10.1002/jssc.201600051] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 02/11/2016] [Accepted: 02/21/2016] [Indexed: 12/28/2022]
Affiliation(s)
- Chunli Gan
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Lu Liu
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Yan Du
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Liqian Wang
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Mingjie Gao
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Lijun Wu
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| | - Chunjuan Yang
- College of Pharmacy; Harbin Medical University; Nangang District Harbin China
| |
Collapse
|